AWA
ALXN

Arkadios Wealth Advisors’s Alexion Pharmaceuticals ALXN Stock Holding History

Arkadios Wealth Advisors’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-2,368
Closed -$435K – 2125
2021
Q2 		$435K Sell
2,368
-359
-13% -$61.6K 0.05% 365
2021
Q1 		$416K Buy
2,727
+129
+5% +$20K 0.07% 287
2020
Q4 		$405K Buy
2,598
+2,514
+2,993% +$323K 0.09% 224
2020
Q3 		$10.4K Hold
84
– – 0.01% 742
2020
Q2 		$9.12K Buy
84
+20
+31% +$2.12K 0.01% 698
2020
Q1 		$5.75K Hold
64
– – ﹤0.01% 759
2019
Q4 		$6.62K Buy
+64
New +$6.84K ﹤0.01% 662

Other funds holding ALXN

BCI
Brinker Capital Investments Berwyn, Pennsylvania $11.7B AUM 21.33% 1-Year Est. Return
NICM
Neo Ivy Capital Management New York $379M AUM 28.34% 1-Year Est. Return
TAIM
TD Ameritrade Investment Management Omaha, Nebraska $9.4B AUM 7.2% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return
RG
Retirement Group San Diego, California $279M AUM 22.21% 1-Year Est. Return
CFO
CVA Family Office Denver, Colorado $950M AUM 20.72% 1-Year Est. Return
MAM
Meeder Asset Management Dublin, Ohio $1.75B AUM 34.85% 1-Year Est. Return

Arkadios Wealth Advisors's ALXN Position: Q3 2021 in Review

Arkadios Wealth Advisors sold out of Alexion Pharmaceuticals (ALXN) in Q3 2021, closing a stake of 2,368 shares — an estimated $435K sold.

Arkadios Wealth Advisors first reported a position in ALXN in Q4 2019 and held it in 7 quarters. The position peaked at $435K in Q2 2021. 7 funds tracked by Wall St. Rank hold ALXN as of Q3 2021.

  • Arkadios Wealth Advisors reported no remaining Alexion Pharmaceuticals position as of Q3 2021 after selling out during the quarter.
  • Arkadios Wealth Advisors sold 2,368 Alexion Pharmaceuticals shares in Q3 2021, an estimated $435K.
  • Arkadios Wealth Advisors first reported a position in Alexion Pharmaceuticals in Q4 2019 and held it in 7 quarters.
  • Arkadios Wealth Advisors's Alexion Pharmaceuticals position peaked at $435K in Q2 2021.
  • 7 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q3 2021.

Based on Arkadios Wealth Advisors's 13F filing for Q3 2021, filed 19 Oct 2021.